Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-04-06 DOI:10.1080/14796694.2025.2480050

Jason Hafron, Agnes Hong, Michael J Ryan, Hela Romdhani, Frédéric Kinkead, Scott C Flanders, Rana R McKay

{"title":"Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US.","authors":"Jason Hafron, Agnes Hong, Michael J Ryan, Hela Romdhani, Frédéric Kinkead, Scott C Flanders, Rana R McKay","doi":"10.1080/14796694.2025.2480050","DOIUrl":null,"url":null,"abstract":"Aims: Androgen deprivation therapy (ADT) is standard for advanced prostate cancer. Relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, is the only oral ADT, with limited real-world data on therapy persistence and adherence. This retrospective study evaluates persistence and adherence of relugolix, degarelix, and GnRH agonists (leuprolide, goserelin, triptorelin, histrelin) using data from the IBM MarketScan Research Database (Jan 2017 - Dec 2022).Methods: The IBM MarketScan Research Database (1 January 2017 - 31 December 2022) was used for enrollment history and claims. ADT adherence was measured by the proportion of days covered (PDC) at 3, 6, and 12 months, calculated as days on ADT divided by period duration. Kaplan-Meier analysis assessed treatment persistence by measuring time to treatment discontinuation.Results: Relugolix had higher adherence (PDC ≥ 80%) at 12 months (60.8%) compared to degarelix (13.0%) and GnRH agonists (46.3%). Median time to discontinuation was also longer for relugolix (13.5 months) than degarelix (3.1 months) and GnRH agonists (8.8 months). Persistence and adherence rates were higher in metastatic prostate cancer.Conclusions: Findings support relugolix use as an oral treatment due to its favorable persistence and long-term adherence profiles.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-12"},"PeriodicalIF":3.0000,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2480050","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: Androgen deprivation therapy (ADT) is standard for advanced prostate cancer. Relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, is the only oral ADT, with limited real-world data on therapy persistence and adherence. This retrospective study evaluates persistence and adherence of relugolix, degarelix, and GnRH agonists (leuprolide, goserelin, triptorelin, histrelin) using data from the IBM MarketScan Research Database (Jan 2017 - Dec 2022).

Methods: The IBM MarketScan Research Database (1 January 2017 - 31 December 2022) was used for enrollment history and claims. ADT adherence was measured by the proportion of days covered (PDC) at 3, 6, and 12 months, calculated as days on ADT divided by period duration. Kaplan-Meier analysis assessed treatment persistence by measuring time to treatment discontinuation.

Results: Relugolix had higher adherence (PDC ≥ 80%) at 12 months (60.8%) compared to degarelix (13.0%) and GnRH agonists (46.3%). Median time to discontinuation was also longer for relugolix (13.5 months) than degarelix (3.1 months) and GnRH agonists (8.8 months). Persistence and adherence rates were higher in metastatic prostate cancer.

Conclusions: Findings support relugolix use as an oral treatment due to its favorable persistence and long-term adherence profiles.

查看原文本刊更多论文

目的：雄激素剥夺疗法（ADT）是晚期前列腺癌的标准疗法。促性腺激素释放激素（GnRH）受体拮抗剂瑞格列酮是唯一的口服 ADT，但有关治疗持续性和依从性的实际数据有限。这项回顾性研究利用IBM MarketScan研究数据库（2017年1月-2022年12月）的数据评估了瑞格列奈、地加瑞克和GnRH激动剂（亮丙瑞林、戈舍瑞林、曲普瑞林、组瑞林）的治疗持续性和依从性：IBM MarketScan研究数据库（2017年1月1日至2022年12月31日）用于登记历史和索赔。ADT依从性以3、6和12个月的覆盖天数比例（PDC）来衡量，计算方法为ADT天数除以持续时间。Kaplan-Meier分析通过测量终止治疗的时间来评估治疗的持续性：与地加瑞克（13.0%）和GnRH激动剂（46.3%）相比，瑞乐高在12个月时（60.8%）的依从性更高（PDC≥80%）。瑞格列奈的中位停药时间（13.5个月）也长于地加瑞克（3.1个月）和GnRH激动剂（8.8个月）。转移性前列腺癌患者的持续率和坚持率更高：研究结果表明，瑞格列酮具有良好的持续性和长期依从性，因此支持将其作为口服治疗药物使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.